Journal of Clinical Oncology, Vol 15, 3441-3445, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer

MJ Moore, IF Tannock, DS Ernst, S Huan and N Murray
Princess Margaret Hospital, Toronto, Ontario, Canada. malcolm_moore@pmh.toronto.on.ca

PURPOSE: To evaluate the efficacy and toxicity of gemcitabine (2',2'- difluorodeoxycytidine) in previously untreated patients with advanced transitional cell carcinoma. PATIENTS AND METHODS: Forty-one patients with measurable advanced transitional cell carcinoma who had received no prior chemotherapy for metastatic disease were scheduled to receive gemcitabine 1,200 mg/m2 intravenously over 30 minutes on days 1, 8, and 15 of a 28-day cycle. Prior adjuvant or neoadjuvant therapy for locally advanced disease was allowed if this was completed greater than 1 year prior to study entry. All patients were treated on an outpatient basis. RESULTS: There were three complete responses and six partial responses seen in 37 assessable patients, for an overall response rate of nine of 37 (24.3%; 95% confidence interval, 12 to 41). Four patients remain in remission at 14, 23, 24, and 31 months. The median survival was 8 months with 17% of patients alive at 2 years. Treatment generally was well-tolerated with three patients having > or = grade 3 nonhematologic toxicity, five having grade 3 neutropenia, two having grade 3 thrombocytopenia, and two episodes of febrile neutropenia. Most patients were able to receive the drug as scheduled with the primary reason for dose reduction or dose delay being neutropenia. CONCLUSION: Gemcitabine has promising single-agent activity against urothelial cancer with a favorable toxicity profile. Further studies in combination with other active agents are warranted.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				H von der Maase, J Lehmann, G Gravis, H Joensuu, P. Geertsen, J Gough, G Chen, and M Kania A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium Ann. Onc., October 1, 2006; 17(10): 1533 - 1538. [Abstract] [Full Text] [PDF]

				R Sawhney, D Bourgeois, and U. Chaudhary Neo-adjuvant chemotherapy for muscle-invasive bladder cancer: a look ahead Ann. Onc., September 1, 2006; 17(9): 1360 - 1369. [Abstract] [Full Text] [PDF]

				G. Dalbagni, P. Russo, B. Bochner, L. Ben-Porat, J. Sheinfeld, P. Sogani, M. S. Donat, H. W. Herr, and D. Bajorin Phase II Trial of Intravesical Gemcitabine in Bacille Calmette-Guerin-Refractory Transitional Cell Carcinoma of the Bladder J. Clin. Oncol., June 20, 2006; 24(18): 2729 - 2734. [Abstract] [Full Text] [PDF]

				C. Theodore, F. Bidault, N. Bouvet-Forteau, M. Abdelatif, K. Fizazi, M. di Palma, P. Wibault, R. de Crevoisier, and A. Laplanche A phase II monocentric study of oxaliplatin in combination with gemcitabine (GEMOX) in patients with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract Ann. Onc., June 1, 2006; 17(6): 990 - 994. [Abstract] [Full Text] [PDF]

				C. P. Lee, M. J.A. de Jonge, A. E. O'Donnell, K. L. Schothorst, J. Hanwell, J. B. Chick, R. A. Brooimans, L. M. Adams, D. W. Drolet, J. S. de Bono, et al. A Phase I Study of a New Nucleoside Analogue, OSI-7836, Using Two Administration Schedules in Patients with Advanced Solid Malignancies. Clin. Cancer Res., May 1, 2006; 12(9): 2841 - 2848. [Abstract] [Full Text] [PDF]

				A. Bamias, I. Tiliakos, M.-D. Karali, and M. A. Dimopoulos Systemic chemotherapy in inoperable or metastatic bladder cancer Ann. Onc., April 1, 2006; 17(4): 553 - 561. [Abstract] [Full Text] [PDF]

				E. Kent, H. Sandler, J. Montie, C. Lee, J. Herman, P. Esper, J. Fardig, and D. C. Smith Combined-Modality Therapy With Gemcitabine and Radiotherapy As a Bladder Preservation Strategy: Results of a Phase I Trial J. Clin. Oncol., July 1, 2004; 22(13): 2540 - 2545. [Abstract] [Full Text] [PDF]

				W. Zoli, L. Ricotti, A. Tesei, P. Ulivi, A. G. Campani, F. Fabbri, R. Gunelli, G. L. Frassineti, and D. Amadori Schedule-Dependent Cytotoxic Interaction between Epidoxorubicin and Gemcitabine in Human Bladder Cancer Cells in Vitro Clin. Cancer Res., February 15, 2004; 10(4): 1500 - 1507. [Abstract] [Full Text] [PDF]

				P. J. Mansky, J. Grem, D. B. Wallerstedt, B. P. Monahan, and M. R. Blackman Mistletoe and Gemcitabine in Patients with Advanced Cancer: A Model for the Phase I Study of Botanicals and Botanical-Drug Interactions in Cancer Therapy Integr Cancer Ther, December 1, 2003; 2(4): 345 - 352. [Abstract] [PDF]

				C. Nabhan, D. Gajria, N. L. Krett, V. Gandhi, K. Ghias, and S. T. Rosen Caspase Activation Is Required for Gemcitabine Activity in Multiple Myeloma Cell Lines Mol. Cancer Ther., November 1, 2002; 1(13): 1221 - 1227. [Abstract] [Full Text] [PDF]

				G. Dalbagni, P. Russo, J. Sheinfeld, M. Mazumdar, W. Tong, F. Rabbani, M. S. Donat, H. W. Herr, P. Sogani, D. dePalma, et al. Phase I Trial of Intravesical Gemcitabine in Bacillus Calmette-Guerin-Refractory Transitional-Cell Carcinoma of the Bladder J. Clin. Oncol., August 1, 2002; 20(15): 3193 - 3198. [Abstract] [Full Text] [PDF]

				M. J. Egorin, E. G. Zuhowski, C. M. McCully, S. M. Blaney, J. Z. Kerr, S. L. Berg, and F. M. Balis Pharmacokinetics of Intrathecal Gemcitabine in Nonhuman Primates Clin. Cancer Res., July 1, 2002; 8(7): 2437 - 2442. [Abstract] [Full Text] [PDF]

				D. Pectasides, J. Glotsos, N. Bountouroglou, A. Kouloubinis, N. Mitakidis, N. Karvounis, N. Ziras, and A. Athanassiou Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial Ann. Onc., February 20, 2002; 13(2): 243 - 250. [Abstract] [Full Text] [PDF]

				A. A. Meluch, F. A. Greco, H. A. Burris III, T. O'Rourke, G. Ortega, R. G. Steis, L. H. Morrissey, V. Johnson, and J. D. Hainsworth Paclitaxel and Gemcitabine Chemotherapy for Advanced Transitional-Cell Carcinoma of the Urothelial Tract: A Phase II Trial of the Minnie Pearl Cancer Research Network J. Clin. Oncol., June 15, 2001; 19(12): 3018 - 3024. [Abstract] [Full Text] [PDF]

				M. Hussain, U. Vaishampayan, W. Du, B. Redman, and D. C. Smith Combination Paclitaxel, Carboplatin, and Gemcitabine Is an Active Treatment for Advanced Urothelial Cancer J. Clin. Oncol., May 1, 2001; 19(9): 2527 - 2533. [Abstract] [Full Text] [PDF]

				J. Bellmunt, V. Guillem, L. Paz-Ares, J. L. Gonzalez-Larriba, J. Carles, E. Batiste-Alentorn, A. Saenz, M. Lopez-Brea, A. Font, M. Nogue, et al. Phase I-II Study of Paclitaxel, Cisplatin, and Gemcitabine in Advanced Transitional-Cell Carcinoma of the Urothelium J. Clin. Oncol., September 18, 2000; 18(18): 3247 - 3255. [Abstract] [Full Text] [PDF]

				H. von der Maase, S.W. Hansen, J.T. Roberts, L. Dogliotti, T. Oliver, M.J. Moore, I. Bodrogi, P. Albers, A. Knuth, C.M. Lippert, et al. Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study J. Clin. Oncol., September 17, 2000; 18(17): 3068 - 3077. [Abstract] [Full Text] [PDF]

				A. P. Venook, M. J. Egorin, G. L. Rosner, D. Hollis, S. Mani, M. Hawkins, J. Byrd, R. Hohl, D. Budman, N. J. Meropol, et al. Phase I and Pharmacokinetic Trial of Gemcitabine in Patients With Hepatic or Renal Dysfunction: Cancer and Leukemia Group B 9565 J. Clin. Oncol., July 14, 2000; 18(14): 2780 - 2787. [Abstract] [Full Text] [PDF]

				E. J. Small, D. Lew, B. G. Redman, D. P. Petrylak, N. Hammond, H. M. Gross, J. A. Eastham, and E. D. Crawford Southwest Oncology Group Study of Paclitaxel and Carboplatin for Advanced Transitional-Cell Carcinoma: The Importance of Survival as a Clinical Trial End Point J. Clin. Oncol., July 1, 2000; 18(13): 2537 - 2544. [Abstract] [Full Text] [PDF]

				D. Kaufman, D. Raghavan, M. Carducci, E. G. Levine, B. Murphy, J. Aisner, T. Kuzel, S. Nicol, W. Oh, and W. Stadler Phase II Trial of Gemcitabine Plus Cisplatin in Patients With Metastatic Urothelial Cancer J. Clin. Oncol., May 9, 2000; 18(9): 1921 - 1927. [Abstract] [Full Text] [PDF]

				L.-Y. Yang, L. Li, H. Jiang, Y. Shen, and W. Plunkett Expression of ERCC1 Antisense RNA Abrogates Gemcitabine-mediated Cytotoxic Synergism with Cisplatin in Human Colon Tumor Cells Defective in Mismatch Repair but Proficient in Nucleotide Excision Repair Clin. Cancer Res., March 1, 2000; 6(3): 773 - 781. [Abstract] [Full Text]

				P. M. Dodd, J. A. McCaffrey, S. Hilton, M. Mazumdar, H. Herr, W. K. Kelly, E. Icasiano, M. G. Boyle, and D. F. Bajorin Phase I Evaluation of Sequential Doxorubicin Gemcitabine Then Ifosfamide Paclitaxel Cisplatin for Patients With Unresectable or Metastatic Transitional-Cell Carcinoma of the Urothelial Tract J. Clin. Oncol., February 14, 2000; 18(4): 840 - 840. [Abstract] [Full Text] [PDF]

				D. F. Bajorin, P. M. Dodd, M. Mazumdar, M. Fazzari, J. A. McCaffrey, H. I. Scher, H. Herr, G. Higgins, and M. G. Boyle Long-Term Survival in Metastatic Transitional-Cell Carcinoma and Prognostic Factors Predicting Outcome of Therapy J. Clin. Oncol., October 1, 1999; 17(10): 3173 - 3181. [Abstract] [Full Text] [PDF]

				M. J. Moore, E. W. Winquist, N. Murray, I. F. Tannock, S. Huan, K. Bennett, W. Walsh, and L. Seymour Gemcitabine Plus Cisplatin, an Active Regimen in Advanced Urothelial Cancer: A Phase II Trial of the National Cancer Institute of Canada Clinical Trials Group J. Clin. Oncol., September 1, 1999; 17(9): 2876 - 2876. [Abstract] [Full Text] [PDF]

				P. J. Cozzi, D. F. Bajorin, W. Tong, H. Nguyen, J. Scott, W. D. W. Heston, and G. Dalbagni Toxicology and Pharmacokinetics of Intravesical Gemcitabine: A Preclinical Study in Dogs Clin. Cancer Res., September 1, 1999; 5(9): 2629 - 2637. [Abstract] [Full Text] [PDF]